Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
BP-C1-57 (10mg): A synthetic pentadecapeptide investigated for its role in angiogenesis, cellular repair pathways, and nitric oxide synthesis
4 How GLP-1 receptor agonists may be integrated into obesity-related KOA care 4.1 From late rescue to earlier, phenotype-oriented intervention In the traditional model, weight loss was recommended broadly but often functioned as a background aspiration rather than a realistic therapeutic milestone
Mitochondrial function
Feature: Targets: Semaglutide: GLP-1 Tirzepatide: GLP-1 + GIP Retatrutide: GLP-1 + GIP + Glucagon Max Weight Loss: Semaglutide: ~15% Tirzepatide: ~22% Retatrutide: 24.2%+ Energy Expenditure: Semaglutide: Low Tirzepatide: Moderate Retatrutide: High Muscle Preservation: Semaglutide: Moderate Tirzepatide: Moderate Retatrutide: Better Dosing Frequency: All: Weekly The addition of glucagon receptor activation gives Retatrutide a unique fat-burning advantage, making it ideal for visceral fat reduction and metabolic reset protocols
Xu Y, Tu W, Sun D, Chen X, Ge Y, Yao S, et al
US$ 24.15
US$ 29.89
US$ 23.89
US$ 27.32
